EDAPTMSInvestor

[EDAPTMSInvestor @EDAPTMSInvestor]

$EDAP TMS

Under the Radar Company with the Potential to Become the Next Medtech Growth Story!

https://t.co/I36IqXxxlq

$ISRG $TMDX $PRCT $SWAV #ProstateCancer #Endometriosis

[EDAPTMSInvestor @EDAPTMSInvestor]

Finally 2 highly reputable analysts from TD COWEN and Mizuho were sitting front row and asking questions during investor day. Likely to see their price targets shortly.

[EDAPTMSInvestor @EDAPTMSInvestor]

$FOCL @EDAPTMS #HIFU #focaltherapy

Focaltherics - Between all the publications/ readouts this year in addition to the huge topline growth the SP will explode this year.

Oslo farp has been confirmed it will be published shortly (focal therapy vs radical surgery)

[EDAPTMSInvestor @EDAPTMSInvestor]

Following dubernard endo publication a formal FDA path will be established for 2nd indication for focal one in USA

HIFI data already driving huge growth and with recent publication of HIFI 2 ( salvage hifu following failed radiation) it just strengthens the data set.

[EDAPTMSInvestor @EDAPTMSInvestor]

@FocalOneHIFU @EDAPTMS on that same vein, we know the 12 month follow-up data on the endo sham group should be available. We anxiously await that data. I implore you to keep the owners of the company up to speed and be accountable to the shareholders on these important updates.

[EDAPTMSInvestor @EDAPTMSInvestor]

@FocalOneHIFU @EDAPTMS @Hiougue The owners of Edap/Focal One would appreciate communication verifying the 3x in French reimbursement rates. We know it's there and I'm sure the investor community would appreciate it as well.

[EDAPTMSInvestor @EDAPTMSInvestor]

@Hiougue @FocalOneHIFU @EDAPTMS

[EDAPTMSInvestor @EDAPTMSInvestor]

French Reimbursement for focal one hifu just 3x. Sales in France and subsequently Europe will explode!

https://t.co/0b9Pq6TMlF

Since this falls in the kidney and urinary tract category, I wonder if it could also apply to endometriosis... $EDAP

[EDAPTMSInvestor @EDAPTMSInvestor]

@MichaelGrand1 @medtechmd

[EDAPTMSInvestor @EDAPTMSInvestor]

This is huge!

Oslo farp in addition to the already published hifi will force nccn hands and we already know the results. Farp just needs to be formally published which I anticipate in the next month or two…

[EDAPTMSInvestor @EDAPTMSInvestor]

@MichaelGrand1 @ZachWil44085644 @medtechmd Just saw this update on another social platform: "major nccn progress"

$EDAP as of last weeks update, nccn created a new principles section for focal therapy.

[EDAPTMSInvestor @EDAPTMSInvestor]

With nccn guidelines in the near future, this means commercial payors will likely come forward with broad coverages and likely 1.5x-2x reimbursement rates vs Medicare.

[EDAPTMSInvestor @EDAPTMSInvestor]

https://t.co/lSae7uZxTG

[EDAPTMSInvestor @EDAPTMSInvestor]

@FocalOneHIFU @EDAPTMS $EDAP

It looks like reimbursement in France for Focal One HIFU is now active as of Sept 1st, 2025! Rates to follow:

[EDAPTMSInvestor @EDAPTMSInvestor]

@EDAPTMS @FocalOneHIFU $EDAP $HIFU
2026 is likely a big year:
Publication of Oslo/ FARP (Level 1 Data) in addition to HIFI Study should bring the following in 2026:

FDA cancer-specific approval
NCCN guideline inclusion
Reimbursement expansion

Hoping for publication by Q4 2025.

[EDAPTMSInvestor @EDAPTMSInvestor]

Updated Data from the Endo study just finished with the follow-up 6-month data from the Sham group patients that were treated...... @EDAPTMS @FocalOneHIFU $EDAP #HIFU

[EDAPTMSInvestor @EDAPTMSInvestor]

Good data.

[EDAPTMSInvestor @EDAPTMSInvestor]

@FocalOneHIFU @EDAPTMS $EDAP #HIFU